Search - tctmd.com

Displaying 1 - 20 of 876

Sort: Relevancy | Date

News Daily News

GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

L.A. McKeown

February 06, 2026

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2026

Caitlin E. Cox

February 02, 2026

News Daily News

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Yael L. Maxwell

January 21, 2026

News Daily News

HF Care Differs Among Asian Subgroups in the US

L.A. McKeown

January 16, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Michael O'Riordan

January 09, 2026

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Remission From Prediabetes Halves CV Risk: Registry Data

Yael L. Maxwell

December 19, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

Todd Neale

December 16, 2025

News Opinion CV Team Dispatch

November 2025 Dispatch for the CV Team

L.A. McKeown

November 24, 2025

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Caitlin E. Cox

November 08, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Opinion CV Team Dispatch

October 2025 Dispatch for the CV Team

L.A. McKeown

October 25, 2025

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

Advertisement

GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

TCTMD’s Top 10 Most Popular Stories for January 2026

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

HF Care Differs Among Asian Subgroups in the US

January 2026 Dispatch for the CV Team

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Year in Review: Top Prevention Stories of 2025

Remission From Prediabetes Halves CV Risk: Registry Data

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

November 2025 Dispatch for the CV Team

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

October 2025 Dispatch for the CV Team

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content